Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis

K. Suzuki, K. Sunami, K. Ohashi, S. Iida, Takehiko Mori, H. Handa, K. Matsue, M. Miyoshi, E. Bleickardt, M. Matsumoto, M. Taniwaki

研究成果: Letter

5 引用 (Scopus)
元の言語English
記事番号e540
ジャーナルBlood Cancer Journal
7
発行部数3
DOI
出版物ステータスPublished - 2017 3 10

ASJC Scopus subject areas

  • Hematology
  • Oncology

これを引用

Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma : ELOQUENT-2 Japanese patient subanalysis. / Suzuki, K.; Sunami, K.; Ohashi, K.; Iida, S.; Mori, Takehiko; Handa, H.; Matsue, K.; Miyoshi, M.; Bleickardt, E.; Matsumoto, M.; Taniwaki, M.

:: Blood Cancer Journal, 巻 7, 番号 3, e540, 10.03.2017.

研究成果: Letter

Suzuki, K, Sunami, K, Ohashi, K, Iida, S, Mori, T, Handa, H, Matsue, K, Miyoshi, M, Bleickardt, E, Matsumoto, M & Taniwaki, M 2017, 'Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis', Blood Cancer Journal, 巻. 7, 番号 3, e540. https://doi.org/10.1038/bcj.2017.18
Suzuki, K. ; Sunami, K. ; Ohashi, K. ; Iida, S. ; Mori, Takehiko ; Handa, H. ; Matsue, K. ; Miyoshi, M. ; Bleickardt, E. ; Matsumoto, M. ; Taniwaki, M. / Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma : ELOQUENT-2 Japanese patient subanalysis. :: Blood Cancer Journal. 2017 ; 巻 7, 番号 3.
@article{20a43c18fba14065a77fef00386c8f7c,
title = "Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis",
author = "K. Suzuki and K. Sunami and K. Ohashi and S. Iida and Takehiko Mori and H. Handa and K. Matsue and M. Miyoshi and E. Bleickardt and M. Matsumoto and M. Taniwaki",
year = "2017",
month = "3",
day = "10",
doi = "10.1038/bcj.2017.18",
language = "English",
volume = "7",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma

T2 - ELOQUENT-2 Japanese patient subanalysis

AU - Suzuki, K.

AU - Sunami, K.

AU - Ohashi, K.

AU - Iida, S.

AU - Mori, Takehiko

AU - Handa, H.

AU - Matsue, K.

AU - Miyoshi, M.

AU - Bleickardt, E.

AU - Matsumoto, M.

AU - Taniwaki, M.

PY - 2017/3/10

Y1 - 2017/3/10

UR - http://www.scopus.com/inward/record.url?scp=85015231066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015231066&partnerID=8YFLogxK

U2 - 10.1038/bcj.2017.18

DO - 10.1038/bcj.2017.18

M3 - Letter

C2 - 28282035

AN - SCOPUS:85015231066

VL - 7

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 3

M1 - e540

ER -